Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.

Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, Churchill D, Cromarty B, Das S, Fisher M, Freedman A, Geretti AM, Johnson M, Khoo S, Leen C, Nair D, Peters B, Phillips A, Pillay D, Pozniak A, Walsh J, Wilkins E, Williams I, Williams M, Youle M; BHIVA Treatment Guidelines Writing Group.

HIV Med. 2008 Oct;9(8):563-608. doi: 10.1111/j.1468-1293.2008.00636.x. No abstract available.

2.

[Antiretroviral therapy in 2004].

Jablonowski H.

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:46-8, 50-1. German.

PMID:
15373049
3.

New antiretroviral drugs and approaches to HIV treatment.

Paredes R, Clotet B.

AIDS. 2003;17 Suppl 4:S85-96. Review. No abstract available.

PMID:
15080184
4.

[Simplification of the antiretroviral regimens. A need to guarantee the long-term control of HIV infection].

Barreiro García P, Soriano Vázquez V.

Rev Clin Esp. 2004 Apr;204(4):212-4. Spanish. No abstract available.

PMID:
15104931
5.

Darunavir: after multiple antiretroviral treatment failure: another option.

[No authors listed]

Prescrire Int. 2008 Jun;17(95):109.

PMID:
18629967
6.

[Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].

Gemeinsame Erklärung der Deutschen AIDS-Gesellschaft (DAIG); Osterreichischen AIDS-Gesellschaft (OAG).

Dtsch Med Wochenschr. 2009 Jan;134 Suppl 1:S4-15. doi: 10.1055/s-0028-1123965. Epub 2009 Jan 26. Review. German. No abstract available.

PMID:
19172554
7.

Managing HIV/AIDS patients.

Paul SM, Sensakovic J, Podhurst LS, Morgan DH, Triano-Davis W.

N J Med. 1998 May;95(5):55-60. Review. No abstract available.

PMID:
16013158
8.

[Guidelines for antiretroviral therapy of human immunodeficiency virus (HIV)-infected subjects in the Czech Republic].

Sedlácek D, Stanková M, Machala L, Rozsypal H, Snopková S, Dostál V, Kolcáková J, Dlouhý P, Jerhotová Z.

Klin Mikrobiol Infekc Lek. 2007 Feb;13(1):28-34. Czech.

PMID:
17417753
9.

Quality of life after starting highly active antiretroviral therapy for chronic HIV-1 infection at different CD4 cell counts.

Nieuwkerk PT, Hillebrand-Haverkort ME, Vriesendorp R, Frissen PH, de Wolf F, Sprangers MA; ATHENA Study Group.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):600-1. No abstract available.

PMID:
17704686
10.

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peter B, Phillips A, Pillay D, Wilkins E, Williams I, Youle M; BHIVA Writing Committee BHIVA Executive Committee.

HIV Med. 2003 Oct;4 Suppl 1:1-41. No abstract available.

11.

Toxicities of antiretroviral therapy in children.

Nwaobasi E, Oleske JM.

AIDS Read. 2006 Oct;16(10):537-40, 544-6,549-50, 552-4.

PMID:
17096472
12.

Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 Window Trial.

Charreau I, Jeanblanc G, Tangre P, Boyer L, Saouzanet M, Marchou B, Molina JM, Aboulker JP, Durand-Zaleski I; ANRS 106 Study Group.

J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):416-21. doi: 10.1097/QAI.0b013e31818a657c.

PMID:
18931625
13.

[How long is the anti-retroviral therapy?].

Martín MT, Codina C.

Farm Hosp. 2007 Jul-Aug;31(4):197-9. Spanish. No abstract available.

14.

German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004).

Salzberger B, Marcus U, Vielhaber B, Arasteh K, Gölz J, Brockmeyer NH, Rockstroh J.

Eur J Med Res. 2004 Nov 29;9(11):491-504.

PMID:
15649858
15.

Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract.

Pasquier CJ, Moinard N, Sauné K, Souyris C, Lavit M, Daudin M, Izopet J, Bujan L.

AIDS. 2008 Sep 12;22(14):1894-6. doi: 10.1097/QAD.0b013e3283101281. No abstract available.

PMID:
18753873
16.

[Antiretroviral therapy suppression: already a new strategy?].

Viciana Fernández P, Mata Alcázar-Caballero R, López Cortés LF.

Farm Hosp. 2004;28(6 Suppl 1):85-91. Spanish. No abstract available.

17.

[Revised guideline "Antiretroviral Treatment"].

Werkgroep antiretrovirale behandeling van de Nederlandse Vereniging van Aids Behandelaren.

Ned Tijdschr Geneeskd. 2005 Oct 22;149(43):2399-405. Review. Dutch.

PMID:
16277129
18.

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.

J Infect Dis. 2009 Nov 15;200(10):1490-7. doi: 10.1086/644598.

PMID:
19832114
19.

The long-term consequences of antiretroviral therapy.

Smith D.

J HIV Ther. 2006 Jun;11(2):24-5. Review. No abstract available.

PMID:
16981592
20.

Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation.

Moreno A, Pérez-Elías MJ, Casado JL, Fortún J, Bárcena R, Quereda C, Del Campo S, Gutiérrez C, Pastor O, Nuño J, Fernandez A, Moreno S.

Liver Transpl. 2010 Apr;16(4):530-2. doi: 10.1002/lt.22005. No abstract available.

Supplemental Content

Support Center